Pharmacodynamics II Flashcards
What is structural specificity?
– there will be some degree of specificity for the drug
What is the pharmacophore?
The part of the receptor that recognizes and “binds” the drug is the “pharmacophore” or drug recognition site.
How do receptors exhibit stereospecificity?
Receptors generally exhibit stereospecificity for drugs containing asymmetric carbon atoms.
Stereospecificity – either all activity will reside in one isomer or one of the isomers will be more potent than the other
How will increasing dose of a drug affect response of receptors?
Saturability – receptors exist in finite numbers and can be saturated by high concentration (doses) of drugs. Increasing dose will increase response- only up to some maximal effect.
Pharmacological Response – there will be some quantitative relationship between the magnitude of the response and the total number of receptors occupied.
This will depend on:
- the amount of drug reaching its site of action
- the specific drug-receptor interaction at that site (e.g. coupling efficiency)
- the functional status of the receptor and/or target cell (e.g. desensitization or supersensitivity)
What is Bmax? How can it be altered?
receptors are dynamic entities whose cellular steady state levels (Bmax) can be affected by pharmacologic, physiologic and pathologic factors.
What are the possible effects of a drug binding to an intracellular receptor?
(What kind of drug can bind? Where are these receptors?
They exist in the cytosol and can bind
biologic compounds that are sufficiently lipid soluble to cross the plasma membrane
The binding of the compound may:
(1) stimulate an intracellular enzyme (e.g. soluble guanylyl cyclase) or
(2) regulate cellular localization of the receptor and alter transcription of genes (e.g.
the glucocorticoid receptor).
What are “gene active” receptors?
When binding of a drug to intracellular receptor regulates the cellular localization of the receptor and alters transcription of genes.
“GENE ACTIVE” receptors since they bind to promoters to
stimulate the transcription of genes in the nucleus.
What are the Therapeutic Consequences of Gene Active Receptors ?
There is a lag period (30 min – few hours) before the effects may be observed. Why ?
– this is due to the time to synthesize new proteins; much longer than the time for other receptors to produce their effects.
What are the Therapeutic Consequences of Gene Active Receptors ?
The effects of gene active receptors may persist for hours or days after the agonist is gone. Why?
this is due to the slow turnover of enzymes or proteins synthesized in response to receptor activation
What is the implication of “gene active” receptors in regards to therapeutic or toxic effects?
- the therapeutic or toxic effects will decrease slowly.
- there is no simple temporal relationship between plasma drug levels and the magnitude of the effect, therefore; - activation of the gene, and its effects, may long outlast the presence of the drug in the body.
What are the 3 types of Plasma Membrane receptors?
- Ligand-Regulated Transmembrane Enzymes including Protein Tyrosine Kinase and Cytokine Receptors
- . Ligand-Gated Channel Receptors.
- G-Protein Family of Transmembrane Enzymes
Protein Tyrosine Kinase (or Serine Kinase/ Guanylyl Cyclase) is an example of what type of receptor? Describe.
A. Receptor polypeptides that cross the membrane once and consist of an extracellular binding domain and an intracellular enzymatic domain (may be tyrosine or serine kinase or guanylyl cyclase)
B. Once activated, these receptors can phosphorylate tyrosines or serines on various downstream proteins.
C. Autophosphorylation of tyrosines on the receptor’s cytoplasmic side can intensify or prolong the duration of receptor activation (e.g. autophosphorylation of the insulin receptor persists long after insulin dissociates from the receptor).
How might ligand binding affect the response of ligand-regulated TM enzyme receptors?
Subject to receptor down-regulation via endocytosis and degradation of receptors –ligand binding may also induce an accelerated endocytosis that could limit the intensity or duration of the drug effects.
Describe the cytokine receptor. What does it respond to?
Closely resemble the tyrosine kinase receptors but utilize a separate protein tyrosine kinase that binds non-covalently and is not intrinsic to the receptor.
These receptors respond to a heterologous group of peptide ligands such as growth hormone and other regulators of growth and differentiation.
Describe the cytokine receptor mechanism.
- Ligand binding induces conformational change and receptor dimerization.
- Dimerization allows JAKs to be activated & phosphorylate tyrosine residues on the receptor.
- Phosphorylation of tyrosine on the receptor facilitates the binding of STAT proteins(Signal Transducers and Activators of Transcription).
- The bound STATs are then phosphorylated by the JAKs
- Two STATS dimerize & the dimer dissociates, travels to the nucleus and regulates gene transcription.
What is an example of the ligand gated channel receptor?
the Nicotinic Cholinergic Receptor
What are the signaling characteristics of the ligand gated channel receptors?
- A pentamer consisting of 4 types of glycoprotein subunits (alpha2 beta gamma delta) that form a cylindrical structure containing the channel.
- Acetylcholine binding to the α subunits produce a conformational change and transient opening of the channel.
- The open channel allows sodium ions to pass from the extracellualr fluid into the cell.
- The time between binding and response is in milliseconds which provides for rapid information transfer; much quicker than other signaling mechanisms that require seconds, minutes or hours to produce their effects.
What is the quickest signaling mechanism? Slowest?
Ligand gated channel receptors - The time between binding and response is in milliseconds which provides for rapid information transfer; much quicker than other signaling mechanisms that require seconds, minutes or hours to produce their effects.
slowest- Gene active?
Describe G- protein linked receptors. What are some key aspects about them?
- A single polypeptide chain that traverses the plasma membrane 7 times (aka serpentine receptors)
- The amino terminus is in the extracellular side while the carboxy terminus resides on the intracellualr side.
- The extracellular region contains the ligand or drug recognition site (pharmacophore).
- The third intracellular loop regulates the ability to interact with specific G-proteins while the carboxy terminus contains sites (serine residues) that are subject to phosphorylation and regulation of receptor function.
- Activation of G proteins conveys the effects of the drug to the second messenger enzymes.
What is the role of G proteins?
proteins that act as intermediates in the
transfer of information between the receptor and the second messenger. They are composed
of alpha, beta and gamma subunits that exist together as a trimer. Different G proteins mediate
the stimulatory and inhibitory effects on adenylyl cyclase and the activation of phospholipase C.
These G proteins are referred to as Gs, Gi and Gq and differ primarily in their alpha subunits
What is the mechanism of activation of G protein coupled receptors?
a) Agonist binds to receptor and facilitates its association with a G‐protein (i.e. formation of a ternary complex)
b) Formation of the Ternary Complex facilitates the binding of GTP rather than GDP to the Gprotein.
c) Binding of GTP to the alpha subunit dissociates it from the beta‐gamma subunits, receptor and
agonist.
d) The GTP‐bound G‐protein is the active intermediate which changes the activity of the effector
component, usually an ion channel or enzyme such as adenylyl cyclase or phospholipase.
e) The G‐protein remains active until a GTPase converts GTP to GDP reforming the original nonreactive
G‐protein.
The separation of receptor activation from G‐protein mediated activation of the effector
facilitates amplification of the transduced signal.
Reversible phosphorylation is a common theme in these signaling mechanisms. Why?
provides for amplification (activation of multiple substrates) and flexible regulation (e.g.
via cellular availability of particular kinases or kinase substrates).
What is the following an example of?
A. actions at same receptor
B. action at identical receptor but in different tissues or affecting different effector pathways
C. actions mediated by different types of receptors)
Ex:
direct pharmacologic extension of the therapeutic
actions of the drug (e.g. excessive bleeding caused by anticoagulant therapy).
Actions at the same receptor ‐ direct pharmacologic extension of the therapeutic
actions of the drug (e.g. excessive bleeding caused by anticoagulant therapy).
manage dose
monitor effect
toxicity may be minimized or prevented by careful management of dose and
monitoring of effect, or by not administering the drug at all.
